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Background: Glaucoma can be associated with an increase in the occurrence of ocular sur-
face disease (OSD) symptoms. The objective of this study was to examine the prevalence of 
ocular surface complaints in patients with glaucoma who used topical intraocular pressure 
(IOP)-lowering therapies.
Methods: In this multicenter, international, noninterventional study, adults with glaucoma or 
ocular hypertension who were using 1 or more topical IOP-lowering medications completed 
the Ocular Surface Disease Index (OSDI) questionnaire during a regularly scheduled clinic 
visit. OSDI scores (ranging from 0 to 100) were calculated for each patient. An OSDI 
score $13 indicated a clinically relevant presence of OSD.
Results: Of the 448 patients who were evaluated, 53.3% were women, 61.6% had a diagnosis of 
primary open-angle glaucoma, and the mean age was 63 years. The overall OSD prevalence rate 
in the evaluable population was 59.2%, with 25.7%, 13.2%, and 20.3% of the patients reporting 
mild, moderate, or severe OSD symptoms, respectively. Patients with glaucoma diagnoses of 
less than 6 years had a significantly lower mean OSDI score relative to patients with glaucoma 
diagnoses of 6 years or more (18 [mild OSD] versus 23 [moderate OSD], respectively; P = 0.03). 
As the number of IOP-lowering treatments increased from one or two medications to three or 
four medications, the mean OSDI score increased from mild to moderate, though the difference 
in scores was not statistically significant (P = 0.15).
Conclusions: OSD was highly prevalent in this population of glaucoma patients who were 
using IOP-lowering medications. Longer duration since diagnosis was significantly correlated 
with worsening of OSD symptoms. Increases in the number of medications applied also showed 
a clinically relevant increase in OSD symptom severity.
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Introduction
Ocular surface disease (OSD) is a multifactorial ocular condition that results from 
inadequate tear film production and/or increased tear evaporation, and may involve tear 
film degradation as well as damage to the ocular surface.1 Ocular surface damage may 
be triggered by noninfectious irritation of the conjunctival and corneal surface, which, 
in conjunction with a compromised tear film, may aggravate the signs and symptoms 
of OSD and may leave the ocular surface vulnerable to further injury.2–4
Individuals with OSD may experience a number of ocular symptoms at varying 
levels of severity, including dryness, burning/stinging, itching, irritation, tearing, 
  photophobia, foreign body sensation, grittiness, redness, and blurred vision.5 
  Additionally, patients with OSD may or may not have clinically meaningful signs, 
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such as rapid tear film breakup, high tear osmolarity, and 
increased ocular surface staining.1 Studies suggest that OSD 
negatively impacts visual function; the ability to carry out 
daily tasks (eg, driving and participating in sports and other 
leisure activities, such as reading and cooking); and overall 
quality of life.6,7
Approximately 15% of the general elderly population 
experiences some level of OSD.8 Patients with glaucoma 
and ocular hypertension, however, have been shown to suf-
fer OSD at a higher prevalence rate than patients without 
these ocular conditions.2 The etiology of OSD in glaucoma 
patients is thought to be multifactorial: while both condi-
tions are common in the elderly, the presence of additional 
anterior segment ocular disorders (eg, allergy, blepharitis, 
dry eye, or eyelid anatomical abnormalities) may further 
contribute to the onset of OSD. In addition, substantial atten-
tion has been focused on the chronic use of topical ocular 
medications in this population.2,4,5 Specifically, medications 
intended to lower intraocular pressure (IOP) are generally 
administered several times a day, and patients with chronic 
conditions like glaucoma and ocular hypertension require 
long-term use and/or multiple medications to achieve and 
maintain the desired IOP-lowering effects.9 Topical ocular 
IOP-lowering drugs, however, can trigger or exacerbate 
OSD by inducing ocular surface damage, especially if they 
contain preservatives, particularly benzalkonium chloride 
(BAK).5,9,10 The objective of the current study was therefore 
to examine the overall prevalence of OSD in an international 
population of glaucoma patients who were taking one or more 
IOP-lowering medications.
Methods
Study design
This was a multicenter, international, noninterventional, 
single-visit study designed to evaluate the prevalence of 
OSD in patients with glaucoma. Upon entry, all participat-
ing patients provided their written informed consent. An 
  Institutional Review Board/Independent Ethics Committee 
in each associated country approved the protocol and the 
participating investigator. The study was conducted in accor-
dance with Good Clinical Practices and the ethical principles 
described within the Declaration of Helsinki.
During a regularly scheduled clinic visit, patients who 
met all of the inclusion and none of the exclusion   criteria 
completed the Ocular Surface Disease Index (OSDI) 
  questionnaire. Demographic information, medical histories, 
and concomitant medication usage, including artificial tear 
usage, were recorded for each patient.
Patients
Overall, up to 600 patients were planned for enrollment at 
up to 12 investigational centers located in Europe, Asia, 
Australia, and Latin America. Eligible patients included men 
and women of any race or ethnicity who were 18 years of 
age and older, were diagnosed with glaucoma (closed-angle, 
open-angle, pseudoexfoliation, or pigment dispersion) or 
ocular hypertension, and, at the time of enrollment, were 
using topical ocular medications to lower IOP. Additionally, 
all patients must have had a best-corrected visual acuity of 
at least 20/60 in each eye.
Assessments
Patients who met the entry criteria completed the OSDI. 
Specifically, this instrument is a 12-item, disease-specific 
quality of life questionnaire that is used to quantify the 
impact of dry eye on vision-related quality of life. The 
questionnaire includes three subscales: ocular discomfort 
(OSDI-symptoms); functioning (OSDI-function); and 
environmental triggers (OSDI-triggers). The individual items 
within the subscales refer to a 1-week recall period; possible 
responses to each item refer to the frequency of the associated 
disturbance. Each response was recorded using a scale that 
ranged from 0 (none of the time) to 4 (all of the time). The 
average score was transformed to a scale ranging from 
0 to 100, with higher scores representing greater disabilities. 
The impact of dry eye was then assessed categorically as 
normal (scores of 0–12), mild (scores of 13–22), moderate 
(scores of 23–32), or severe (scores of 33–100), as previously 
described.11–13 The OSDI questionnaire has been reported to 
have excellent test-retest reliability and to effectively classify 
clinically normal, mild to moderate, and severe OSD.14,15
Statistics
All analyses were conducted using data from patients who 
satisfied the entry criteria (ie, the evaluable patients). The 
numbers and percentages of glaucoma patients who had 
OSDI scores indicating a normal ocular surface or   indicating 
the presence of mild, moderate, or severe OSD were 
tabulated. Correlations between the mean OSDI score and the 
time since glaucoma diagnosis, as well as the number of IOP-
lowering medications used, were also tabulated. Specifically, 
the mean OSDI scores were summarized by the categorical 
time since glaucoma diagnosis (, mean   number of years 
since diagnosis and $ mean number of years since diagnosis) 
and, separately, by the categorical number of IOP-lowering 
medications used (1 or 2 medications and 3 or 4 medications); 
comparisons within subgroups were   performed using either 
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an analysis of variance or a t-test with inferences drawn at 
an alpha level of 0.05.
Results
Patient characteristics and disposition
A total of 458 patients were enrolled across eight 
investigational centers located in Argentina, Australia, 
China, Colombia, Germany, India, Mexico, and Spain. Of 
the enrolled patients, 448 met all of the entry criteria and 
were included in the analyses. The evaluable patients were 
19 to 90 years of age, inclusive, with a mean (standard 
deviation [SD]) age of 63 (14) years. Overall, 56.0% of the 
patients were Caucasian and 53.3% of the patients were 
women. Most of the patients (78.6%) had a diagnosis of either 
primary open-angle glaucoma (61.6%) or ocular hypertension 
(17.0%) as shown in Table 1.
Prevalence of ocular surface disease
More than half of the total study population had   abnormal 
OSDI scores (265 of 448 patients), with an overall OSD preva-
lence rate of 59.2% (95% confidence interval: 54.6%–63.7%). 
The mean age of patients with normal OSDI scores 
was 62 (14) years, which was not significantly different 
(P = 0.18) from the mean age of patients with abnormal 
OSDI scores, at 64 (14) years. Based on their OSDI scores, 
of the 448 evaluated patients, 115 (25.7%) had mild OSD, 
59 (13.2%) had moderate OSD, and 91 (20.3%) had severe 
OSD (Figure 1).
Correlation of ocular surface disease 
with time since glaucoma diagnosis
The mean (SD) time since glaucoma diagnosis in this 
population was 6.0 (5.4) years. Using this as the basis for 
dividing patients into categories of durations since their 
glaucoma diagnosis (ie, $6 years and ,6 years), a direct 
  correlation was shown between an increase in time since 
glaucoma diagnosis and higher (worse) OSDI scores 
(Table 2). On average, patients who had a glaucoma diagnosis 
of less than 6 years had a mean (SD) OSDI score of 18 (16) 
units, which is indicative of mild OSD, while patients who 
had a glaucoma diagnosis of 6 years or longer had a mean 
(SD) OSDI score of 23 (21) units, which is indicative of 
moderate OSD. The OSDI scores were significantly different 
between groups (P = 0.03), but the ages were not significantly 
different between groups (P = 0.11) (Table 2).
Correlation of ocular surface disease 
with number of IOP-lowering 
medications
On average, patients used 1.9 (1.3) IOP-lowering medications. 
A direct correlation was shown between an increase in the 
number of IOP-lowering medications used by patients and 
higher (worse) OSDI scores. As the number of IOP-lowering 
medications increased from one or two to three or four, the 
mean (SD) OSDI score increased from 20 [17] units (mild 
severity) to 23 [21] units (moderate severity). Although the 
difference in scores may have been clinically relevant in 
terms of the designations on the OSDI scale, the difference 
was not statistically significant (P = 0.15) (Table 3). Note 
that 17 patients who reported using 5 or more IOP-lowering 
medications were not evaluated, since this claim seemed 
unlikely to have reflected current use and more likely to have 
reflected a history of prescription uses.
Correlation of ocular surface disease 
with race/geography
Patients who were Latino or of mixed race/ethnicity, all 
of whom were enrolled at clinics in Latin America, had a 
Table  1  Demographic  and  baseline  characteristics  (evaluable 
patients)
Total 
(n = 448)
Age, years
  Mean (standard deviation) 63 (14)
  Range (minimum, maximum) (19, 90)
Sex, n (%)
  Men 209 (46.7)
  Women 239 (53.3)
Race, n (%)
  Caucasian 251 (56.0)
  Black 0 (0.0)
  Asian 117 (26.1)
  Other 80 (17.9)
Glaucoma diagnosis, n (%)
  Ocular hypertension 76 (17.0)
  Primary open-angle glaucoma 276 (61.6)
  Open-angle glaucoma with pseudoexfoliation 53 (11.8)
  Open-angle glaucoma with pigment-dispersion 6 (1.3)
  Closed-angle glaucoma 37 (8.3)
Time since glaucoma diagnosis, years (n = 387)
  Mean (standard deviation) 6.0 (5.4)
 , 6 years, n (%) 250 (64.6)
 $ 6 years, n (%) 137 (35.4)
number of IOP-lowering medications
  Mean (standard deviation) 1.9 (1.3)
  1 or 2, n (%) 348 (77.7)
  3 or 4, n (%) 83 (18.5)
 $ 5, n (%) 17 (3.8)
Abbreviation: IOP, intraocular pressure.
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mean (SD) OSDI score of 29 (21) units, indicating moderate 
OSD. This score was significantly higher than the score for 
Asian patients (mean [SD] = 17 [17] units; P = 0.0001) and 
Caucasian patients (mean [SD] = 20 [17] units; P = 0.0009): 
both of these groups had OSDI scores indicating mild OSD. 
There were no significant differences in OSDI scores between 
Asian and Caucasian patients (data not shown in tables or   
figures).
Discussion
OSD is commonly observed in individuals who suffer from 
glaucoma and/or ocular hypertension. The prevalence rate 
of OSD reported in this international study (wherein 59.2% 
of patients with glaucoma had OSD) is consistent with 
the prevalence rate of OSD (59%) reported in a previous 
  cross-sectional study of patients in the United States who had 
open-angle glaucoma or ocular hypertension and who com-
pleted the OSDI questionnaire.11 Additionally, in a study of 
more than 20,000 adults in Germany, approximately 53% of 
the patients with glaucoma were also diagnosed with dry 
eye based on clinical tests including Schirmer’s test, corneal 
fluorescein staining, and measurements of tear meniscus and 
tear film break up time.16 While the approach was different, 
the result is consistent with that obtained in the current study. 
Further, the prevalence of severe OSD in the study reported 
here (20.3% of patients with glaucoma) is consistent with the 
prevalence of severe OSD in a previously conducted study 
(27%) that similarly used the OSDI questionnaire.11
Preservatives are added to ophthalmic products pack-
aged in multi-dose containers in order to increase their shelf 
life and decrease their risk of contamination.10 Although 
preserved ophthalmic products have been approved as safe 
for use on the basis of results from short-term to medium-
term clinical studies, frequent and long-term instillation of 
preserved ophthalmic products (over the course of many 
years) may result in ocular surface damage caused by 
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Figure 1 number and percentage of glaucoma patients with Ocular Surface Disease Index scores indicating normal ocular surface or the presence of mild, moderate, or 
severe dry eye/ocular surface disease complaints (evaluable patients).
Abbreviation: OSDI, Ocular Surface Disease Index.
Table 2 Correlation between Ocular Surface Disease Index score and the time since glaucoma diagnosis (evaluable patients)
Time since glaucoma  
diagnosis (years)
Na OSDI Age, years
Mean SD P-valueb Mean SD P-valuec
,6 years 250 18 16 0.03 61 14 0.11
$6 years 137 23 21 64 14
Notes: aThe time since glaucoma diagnosis for 61 patients was unknown; bP-value was calculated from an analysis of variance; cP-value was calculated by t-test.
Abbreviations: OSDI, Ocular Surface Disease Index; SD, standard deviation.
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the preservative.17 BAK is the most widely used preservative 
in ophthalmic preparations due to its broad spectrum of 
antimicrobial efficacy and its effect on the tight junctions 
between epithelial cells in the cornea.18 However, BAK has 
been shown to induce toxic effects on the cornea and ocular 
tissues.19–21 These toxic effects tend to occur particularly 
after chronic topical ocular use of BAK-containing products 
for the treatment of chronic diseases, such as dry eye and 
glaucoma.
Further, the use of multiple topical ocular therapies may 
increase ocular surface damage due to possible additive 
effects, as well as increase the BAK load (due to multiple 
BAK-preserved ocular preparations).9 This is particularly 
relevant for patients suffering from glaucoma and ocular 
hypertension, since patients with these conditions routinely 
use multiple topical ocular IOP-lowering agents, which can 
be administered several times a day for long periods of time. 
As such, the potential for these patients to develop dry eye 
secondary to the use of topical ocular preserved therapies is 
clinically meaningful. Newer ophthalmic preservatives have 
been developed (eg, Purite®, [Allergan, Irvine, CA]; SofZia® 
buffer system, [Alcon, Fort Worth, TX]; and Polyquad® 
preservative, [Alcon]) and have been used in reformulating 
BAK-preserved IOP-lowering medications. This advance-
ment can offer glaucoma patients alternate therapies that can 
reduce their exposure to BAK and is especially important to 
help preserve the ocular surface health of patients who use 
products or multiple products over many years.19,20
In the present study, patients who had glaucoma histories 
of less than 6 years had a mean OSDI score indicative of mild 
OSD, while patients who had longer glaucoma histories had 
a mean OSDI score that was significantly worse (P = 0.03), 
indicating moderate OSD. The change from mild to moder-
ate OSD appeared to be associated only with duration of 
treatment (P = 0.03), not with patient age (P = 0.11). This 
correlation with duration of diagnosis is consistent with 
previous studies reporting that the occurrence of dry eye 
increased with the durations of glaucoma disease and glau-
coma treatment.12,16
Although there was a clinically relevant difference 
observed in the OSDI score for patients who used one or 
two IOP-lowering medications (mild OSD severity) when 
compared with patients who used three or four IOP-lowering 
medications (moderate OSD severity), this difference was 
not statistically significant (P = 0.15). This result is less con-
clusive than previous studies showing a strong correlation 
between the number of IOP-lowering medications used and 
the presence of dry eye.12,13,16 However, given the issue of 
poor medication adherence,22 patients who reported taking 
their medications may not have been truly compliant to the 
dosing regimen, and may therefore not have experienced the 
adverse effects of topical ocular drug exposure to the fullest 
extent possible.
Finally, in the present study, Asian and Caucasian patients 
had mean OSDI scores indicative of mild OSD, while 
Latino or mixed-race patients (all of whom were enrolled 
at Latin American clinics) had a mean OSDI score that 
was significantly worse (P # 0.0009), indicating moderate 
OSD. A majority of the patients enrolled in the study were 
Caucasian (56.0%), with the remaining patients distributed 
unequally between Asian (26.1%) and other (17.9%) races.
Some limitations of this study were related to the mul-
titude of variables. This was evident in the wide variation 
(ie, large standard deviations) in the mean OSDI scores for 
the population, which rendered data interpretation more 
complicated. The pathogenesis of OSD in glaucoma patients 
is thought to be multifactorial; while the role of preserved 
topical ocular drops in OSD is the most well studied, other 
anterior segment ocular conditions (eg, blepharitis, allergies, 
infections, or anatomic abnormalities of the eyelid[s]) are 
known to exacerbate OSD.2 Collecting data about comorbid 
conditions and determining the impact of all these factors on 
the OSD prevalence was beyond the scope of the objectives 
outlined for this study. For the data that were collected, the 
study could have benefited from a multivariate analysis to 
determine the contribution of the various factors that lead to 
OSD, including age, sex, number of medications, and time 
since diagnosis.
Other limitations of the study were related to the subjec-
tive nature of the data. Relying on self-reported values or 
patient histories for the numbers of IOP-lowering medica-
tions yielded data that were less reliable than values recorded 
by electronic dosage-tracking technologies would have been. 
Moreover, the OSDI is a subjective tool; adding objective 
assessments of the ocular surface could have strengthened 
Table  3  Correlation  between  the  Ocular  Surface  Disease 
Index score and the number of IOP-lowering medications used 
(evaluable patients)
Number of IOP-lowering  
medications
Na OSDI P-valueb
Mean SD
1 or 2 348 20 17 0.15
3 or 4 83 23 21
Notes:  aData  for  17  patients  who  reported  use  of  5  or  more  medications 
were not included in this tabulation; bP-value was calculated from an analysis of 
variance.
Abbreviations:  OSDI,  Ocular  Surface  Disease  Index;  SD,  standard  deviation;   
IOP, intraocular pressure. 
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the study, although the correlation between such signs and 
symptoms has been reported to be poor.23 Despite its various 
limitations, this study clearly supports previous studies that 
have observed a high prevalence of OSD among glaucoma 
patients and have recognized the increase in OSD with both 
increasing time since glaucoma diagnosis, and the use of 
multiple topical ocular preparations.
Conclusions
The data from this international study indicated that more 
than half of the patients with glaucoma experienced some 
level of OSD. There was a statistically significant correlation 
between increased time since glaucoma diagnosis and wors-
ening of OSD symptoms. Further, increases in the number 
of medications applied also showed a clinically relevant 
increase in OSD symptom severity.
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